Scholar Rock Holding Gross Margin 2017-2021 | SRRK

Current and historical gross margin for Scholar Rock Holding (SRRK) over the last 10 years. The current gross profit margin for Scholar Rock Holding as of September 30, 2021 is %.
Scholar Rock Holding Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2021-09-30 $0.02B $0.02B 100.00%
2021-06-30 $0.02B $0.02B 100.00%
2021-03-31 $0.02B $0.02B 100.00%
2020-12-31 $0.02B $0.02B 100.00%
2020-09-30 $0.02B $0.02B 100.00%
2020-06-30 $0.02B $0.02B 100.00%
2020-03-31 $0.02B $0.02B 100.00%
2019-12-31 $0.02B $0.02B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.572B $0.015B
Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88